|Drug Name||GPCR-targeted Project 005|
Prokineticins (PK1 and PK2) are peptide hormones that exert their biological activities, such as modulating cell survival, cell motility, and cell excitability, through two common G-protein-coupled receptors: prokineticin receptor (PKR) 1 and 2. A monoclonal antibody is being developing as an inhibitor of prokineticin receptor 1 (PKR1) for the treatment of inflammation. Early research is under way.
|Target||Prokineticin receptor 1 (PKR1)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||PKR1 inhibitors|
We look forward to hearing from you.